Antiviral perspectives for chikungunya virus
- PMID: 24955364
- PMCID: PMC4052087
- DOI: 10.1155/2014/631642
Antiviral perspectives for chikungunya virus
Abstract
Chikungunya virus (CHIKV) is a mosquito-borne pathogen that has a major health impact in humans and causes acute febrile illness in humans accompanied by joint pains and, in many cases, persistent arthralgia lasting for weeks to years. CHIKV reemerged in 2005-2006 in several parts of the Indian Ocean islands and India after a gap of 32 years, causing millions of cases. The re-emergence of CHIKV has also resulted in numerous outbreaks in several countries in the eastern hemisphere, with a threat to further expand in the near future. However, there is no vaccine against CHIKV infection licensed for human use, and therapy for CHIKV infection is still mainly limited to supportive care as antiviral agents are yet in different stages of testing or development. In this review we explore the different perspectives for chikungunya treatment and the effectiveness of these treatment regimens and discuss the scope for future directions.
References
-
- Hapuarachchi HC, Bandara KBAT, Sumanadasa SDM, et al. Re-emergence of Chikungunya virus in South-east Asia: virological evidence from Sri Lanka and Singapore. Journal of General Virology. 2010;91(4):1067–1076. - PubMed
-
- Arankalle VA, Shrivastava S, Cherian S, et al. Genetic divergence of Chikungunya viruses in India (1963–2006) with special reference to the 2005-2006 explosive epidemic. Journal of General Virology. 2007;88(7):1967–1976. - PubMed
-
- Cherian SS, Walimbe AM, Jadhav SM, et al. Evolutionary rates and timescale comparison of Chikungunya viruses inferred from the whole genome/E1 gene with special reference to the 2005–07 outbreak in the Indian subcontinent. Infection, Genetics and Evolution. 2009;9(1):16–23. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
